PNC-27 for Health & Longevity

Created on 11/14/2026 – Quick Reference based on Evidence Review created using AI4L + evidence-mcp / Opus 5.5 – Audit

PNC-27, a short, laboratory-made chain of amino acids, is promoted as a cancer treatment; its designers report it kills cancer cells by opening holes in their outer membrane while sparing normal cells. The claim rests only on cells grown in the laboratory and on mice, with no human dose or registered trial. Even for early adopters, hazards are better documented than benefits: sold product was found contaminated with bacteria. (Full Review)

Protocol

Standard protocol as used by leading practitioners
There is none
No clinical guideline, trial protocol, product label or published practitioner regimen for human use exists.
Animal regimens, not translatable
40 or 100 mg/kg daily in mice
Intraperitoneal injection (into the abdominal cavity) for two to three weeks.
Competing therapeutic approaches
Intraperitoneal or into the tumor
The unapproved market sold nebulized, intravenous and suppository forms. None has been studied in people.
Time to effect
Membrane rupture in culture
Within 4 hours
Enzyme leakage after exposure.
Slower route
Past 24 hours
Death continued through degradation of a structural membrane protein.
In people
Unknown
No rodent study reports time to tumor response.

Benefits

Contraindications
  • Everyone, outside a registered clinical trial
  • People with weakened immune systems, including after transplant or during cell-killing chemotherapy
  • Pregnant women, young children and older adults
  • People with a potentially curable cancer
Key Interactions
Theoretical (inferred from mechanism)
  • Taxanes (paclitaxel, docetaxel)
  • Anthracyclines (doxorubicin, daunorubicin)
  • Ketone bodies and ketogenic diets
  • Proteasome inhibitors (bortezomib, carfilzomib)
  • mTOR inhibitors and antimetabolites (rapamycin, methotrexate)
  • Antipyretic pain relievers (acetaminophen, ibuprofen)
  • Other membrane-active agents (amphotericin B, antimicrobial peptides)

Risk & Side Effects

  • High:
  • Medium:
  • Low: Infection from contaminated unapproved product; massive gastrointestinal bleeding after infusion; forgone effective cancer treatment
  • Speculative: Off-target mitochondrial membrane disruption; rupture of normal cells carrying surface HDM-2; immunogenicity and infusion reactions

Monitoring

Marker Target Why
Lactate dehydrogenase (LDH) 140–280 U/L Index of cell rupture
Absolute neutrophil count 1,500–8,000 cells/µL Marrow suppression, infection risk
C-reactive protein (CRP) <5 mg/L Flags infection from contaminated product
Alanine aminotransferase (ALT) 7–40 U/L Liver injury
Serum creatinine with eGFR 0.6–1.3 mg/dL Kidney injury

Cadence: No monitoring protocol has been established; if exposure had occurred: baseline before any further exposure, every 1 to 2 weeks while exposure continued, then at 4 weeks and 3 months after it stopped; same-day blood cultures for any fever.

Qualitative Assessment

  • Fever, chills, violent shivering or night sweats
  • Injection-site or inhalation-route symptoms: pain, swelling, redness, cough, breathlessness
  • Unexplained fatigue or malaise distinct from usual disease-related fatigue
  • Cognitive clarity and sleep quality
  • Any change in the symptoms for which the peptide was taken